Enhancing the efficacy of cytotoxic agents for cancer therapy using photochemical internalisation. by Martinez de Pinillos Bayona, A et al.
Enhancing the efﬁcacy of cytotoxic agents for cancer therapy
using photochemical internalisation
Alejandra Martinez de Pinillos Bayona, Caroline M. Moore, Marilena Loizidou, Alexander J. MacRobert
and Josephine H. Woodhams
UCL Division of Surgery and Interventional Sciences, University College London, London, United Kingdom
Photochemical internalisation (PCI) is a technique for improving cellular delivery of certain bioactive agents which are prone
to sequestration within endolysosomes. There is a wide range of agents suitable for PCI-based delivery including toxins, oligo-
nucleotides, genes and immunoconjugates which demonstrates the versatility of this technique. The basic mechanism of PCI
involves triggering release of the agent from endolysosomes within the target cells using a photosensitiser which is selec-
tively retained with the endolysosomal membranes. Excitation of the photosensitiser by visible light leads to disruption of the
membranes via photooxidative damage thereby releasing the agent into the cytosol. This treatment enables the drugs to reach
their intended subcellular target more efficiently and improves their efficacy. In this review we summarise the applications of
this technique with the main emphasis placed on cancer chemotherapy.
Chemotherapy is routine in the treatment of a range of can-
cers, however limitations include systemic toxicity and multi-
drug resistance (MDR),
1,2 and in some cases inadequate
cellular delivery.
3,4 These drawbacks have stimulated consider-
able effort into devising new drug delivery systems (DDS) for
cancer chemotherapy agents including “active” DDS that rely
on an externally applied energy input such as a local electric
ﬁeld (irreversible electroporation) or ultrasound.
5–7 Photo-
chemical Internalisation was originally conceived by Berg et al.
and is also an “active” DDS, since drug delivery is triggered by
the application of light.
8,9 A key advantage of such active DDS
like PCI is that the drug delivery process can be triggered at
the optimum time following drug administration.
Mechanism of PCI
The basic mechanism of PCI involves triggering drug release
from endolysosomes within the target cells using a photosensi-
tiser (PS) which is selectively retained with the endolysosomal
membranes. Excitation of the PS using visible light in the pres-
ence of molecular oxygen leads to disruption of organelle
membranes via photooxidative damage thereby releasing the
drug conﬁned within the organelles (Fig. 1a). This treatment
enables the drugs to reach their intended subcellular target
more efﬁciently which enhances their efﬁcacy. This release
mechanism also serves to counteract enzyme-induced degrada-
tion of some drugs within lysosomes. Because photosensitisers
used for PCI are ﬂuorescent, the photochemically induced dis-
ruption to the endolysosomes can be studied using ﬂuores-
cence imaging.
8,9 Release of ﬂuorescent nanoparticles (NPs)
such as quantum dots initially conﬁned to the endolysosomal
central aqueous compartment concomitant with redistribution
of the PCI photosensitiser has been observed in vitro.
11 Wood-
hams et al. have also demonstrated in vivo light-induced redis-
tribution of a cytotoxic agent, gelonin, in treated rat liver using
immunohistochemistry.
12
For in vivo studies, the PS and bioactive agent are admin-
istered systemically but the enhanced drug delivery induced
by PCI is conﬁned to the zone of illuminated tissue, and PCI
is therefore a site-speciﬁc technique. PCI has been success-
fully used for delivery of anti-cancer cytotoxins such as bleo-
mycin, which is now being tested clinically as discussed
below. With improved intracellular delivery of the bioactive
agents, the administered dose of the agent can be reduced
which is important in the chemotherapy induced toxicity.
The development of PCI as a drug delivery technique
stemmed in part from Photodynamic Therapy (PDT) which
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International Journal of Cancer
IJCFigure 1. Photochemical Internalisation (PCI) vs. Photodynamic Therapy (PDT) The photooxidative damage in PCI is designed to be sub-
lethal but sufﬁcient to release endolysomally entrapped agents such as cytotoxins so that they can reach their intended intracellular targets
(a). Despite common features between PDT and PCI, these two treatments differ in key aspects (b). PCI is a site-speciﬁc DDS
10 therefore,
unlike PDT, the photosensitisers employed in PCI are not used to cause direct cell death.
4 [Color ﬁgure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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tion of the PS results in the production of reactive oxygen
species (ROS), particularly singlet oxygen which can oxidise
important subcellular substrates including membrane compo-
nents such as unsaturated lipids and cholesterol. Like PDT,
PCI also relies on the presence of molecular oxygen for gen-
eration of ROS, although since oxygen solubility in organelle
membranes is relatively high only strongly hypoxic cells
should be unaffected by PCI.
13 However these two treatments
differ in key aspects (Fig. 1b). PCI is a site-speciﬁc drug
delivery technique and thus, unlike PDT, the photosensitisers
employed in PCI are not designed to induce a cytotoxic effect
on their own. Besides, photooxidative damage to endolyso-
somes is not an efﬁcient means of inducing cytotoxicity by
itself.
14 Because the PS is localised in endolysosomal mem-
branes,
15 photochemical damage to the drug cargo should be
limited when light is applied after PS/drug administration,
but if the drug is particularly sensitive to photochemical
damage then a “light-before” regime can be employed
whereby the PS is administered and then light is applied
before drug administration. Although this may appear to be
counter-intuitive, it is believed that the endolysosomal mem-
branes which have already sustained photooxidative damage
will fuse with the membranes of the endolysosomes contain-
ing the drugs thus rendering them more permeable.
16
Selection of photosensitisers for PCI
The photosensitiser should induce efﬁcient generation of
ROS and low aggregation propensity since monomeric PS is
more photoactive, and exhibit strong absorption at red/near-
infrared wavelengths to enable deeper therapeutic efﬁcacy.
PCI is therefore distinct from other light-triggered delivery
systems which rely on UV excitation where tissue penetration is
very limited. In practice, PDT is difﬁcult to suppress in areas
receiving the highest light dose, but PCI will dominate at the
deeper regions of the tumour. Because the PS dose used for PCI
is deliberately low, skin phototoxicity should be less likely.
There are several different photosensitisers currently avail-
able for PCI based on phthalocyanine, porphyrin or chlorin
aromatic dye molecules, typically amphiphilic sulfonated
derivatives where the sulfonate groups are substituted adja-
cently on one side of the aromatic macrocycle. The opposite
unsubstituted side of the macrocycle is therefore relatively
hydrophobic and can reside within the lipid bilayer, allowing
the ionic substituted side to localise at the interface of the
lipid/aqueous phase.
The resulting amphiphilic structure favours endolysosomal
membrane localisation owing to uptake via adsorptive endocy-
tosis with optimum localisation occurring after 18–24 hrs
administration in vitro although longer times have been used
in vivo. AlPcS2a (aluminium phthalocyanine with two sulfonate
groups) is a phthalocyanine-based PS, was initially used for in
vivo PCI owing to its strong absorption in the far-red region
(670 nm).
14,17 Recently, a disulfonated tetraphenylchlorin pho-
tosensitiser TPCS2a (AmphinexV R) has been developed, which
contains far fewer regioisomers than AlPcS2a and is therefore
easier to prepare reproducibly.
18 In 2011, it was proposed as an
optimal PS for clinical PCI and is currently undergoing dose-
escalating phase I/II clinical trials in combination with bleomy-
cin, as discussed below. TPCS2a has suitable photophysical and
photobiological properties for PCI
10 and exhibits strong
absorption at 650 nm. The porphyrin analogue TPPS2a (meso-
tetraphenylporphin with two sulfonate groups on adjacent
phenyl rings), has been extensively used in vitro with good
results but is less suitable for clinical development since its red
absorption is comparatively weak.
14 Sulfonation is not the only
method that has been used to confer amphiphilic properties.
Wang et al. have shown that conjugation of a hydrophobic
porphyrin to a cationic cell penetrating peptide rendered the
porphyrin suitable for PCI.
19
PCI is site selective owing to the light delivery, selective
uptake of photosensitisers in tumours is generally insufﬁcient
to confer treatment selectivity. Enhanced selectivity may be
conferred by passive targeting of the agents through the use
of macromolecular drug carriers and the EPR effect
(enhanced permeability and retention) or actively targeting
the agents by conjugation with ligands such as antibodies. In
the following section, we review cytotoxic cancer chemother-
apy agents that have been used for PCI without active target-
ing followed by a review of results obtained using actively
targeted drugs (see summary Table 1). The examples of drugs
used fall into three categories: the glycopeptide antibiotics
(bleomycin), anthracyclines (mitoxantrone, doxorubicin) and
ribosome inactivating proteins (gelonin, saporin).
Cytotoxic Agents Used With PCI
To date, the majority of PCI studies published focus on mac-
romolecular toxins, however, smaller cytotoxic chemotherapy
drugs such as doxorubicin and bleomycin, have also been
studied. Bleomycin is currently being used in clinical trials of
PCI. In this section we review results using these agents
together with studies on macromolecular carriers incorporat-
ing cytotoxins.
Glycopeptide antibiotics and anthracyclines
Bleomycin is a hydrophilic glycopeptide antibiotic with a rel-
atively high molecular weight (1.4 kDa) which favours uptake
via endocytosis. Cytotoxicity is caused by single and double-
stranded DNA damage. Given alone, bleomycin can result in
pneumonitis and subsequent lung ﬁbrosis at high doses.
38
Enhanced intracellular delivery using PCI is therefore attrac-
tive as a way to reduce the bleomycin dose required, and
potentially the number of treatment cycles.
Berg et al. in 2005 performed PCI both in in vitro and in
vivo human sarcoma, human colorectal adenocarcinoma and
murine colon carcinoma models. TPPS2a (0.7 mgm L
21) and
bleomycin (0.14 IU mL
21) signiﬁcantly enhanced cytotoxicity
by a factor of three compared to bleomycin alone in vitro
38
using illumination after bleomycin administration. The com-
bination of PCI with bleomycin and AlPcS2a, resulted in
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without PCI. Furthermore, the initial weight loss seen in
bleomycin treated animals, was reversed in the PCI group.
38
In a key in vivo study, Norum et al.
45 demonstrated in a
murine ﬁbrosarcoma model that the tumour periphery was
more susceptible to damage using bleomycin PCI compared
to PDT alone with AlPcS2a. Using histology, a smaller area of
viable peripheral tissue was seen post-PCI for the treated ani-
mals than for PDT alone. The greater cell killing in this
highly proliferating area was not due to higher levels of
AlPcS2a as conﬁrmed in ﬂuorescence studies.
PCI using bleomycin has also been investigated for blad-
der and brain cancer. Arentsen et al. demonstrated the
advantage of bleomycin PCI using a range of chemotherapeu-
tic agents in several human and non-human bladder cancer
cell lines in vitro.
48 Enhanced cell kill using bleomycin PCI
was also observed in glioma cell monolayers and multicellular
spheroids.
50 In vivo studies showed improved survival of ani-
mals bearing the F98 glioma model using a combination of
bleomycin PCI and an epsilon prototoxin which is known to
disrupt the blood-brain barrier versus controls.
51 The combi-
nation of bleomycin with external-beam radiotherapy has
Table 1. Photochemical internalisation (PCI) experimental studies in different cancers
Cancer type
In vivo/
In vitro PS Cytotoxic agents References
Uterus cancer In vitro TPPS2a, ZnPc
1, BPD-MA
1,
3-THPP
2, chlorin e6, AlPcS2a
Doxorubicin, (EGF-) Saporin, (Cetuximab-)
Saporin, Gelonin
9,20–24
Head and
Neck cancer
In vitro TAT-TPP, TPPS2a; AlPcS2a, mTHPC
(and liposomal formulations)
1
Saporin, (Polyamidoamine (PAMAM))
dendrimer-Doxorubicin,
(Polyamidoamine (PAMAM))
dendrimer- Saporin, Bleomycin
19,25–27
Breast cancer In vitro TPCS2a, AlPcS2a, Hypericin
1, TPPS2a (Trastuzumab-) Saporin, (EGF-) Saporin, (IM7-)
Saporin, Mitoxantrone,(scFvMEL-) rGelonin,
(MOC31-) Gelonin, MH3-B1/rGel, Doxorubicin
21,23,28–35
In vivo DPc (DPc/m) Doxorubicin 36
Colon cancer In vitro TPCS2a, AlPcS2a, TPPS2a,
(5-ALA)-induced
protoporphyrin IX (PpIX)
1
(Trastuzumab-) Saporin, (MOC31-) Gelonin,
(Cetuximab-) Saporin, (IM7-) Saporin
22,28,29,34,37
In vivo AlPcS2a,TPCS2a, mTHPC
1 Bleomycin, Gelonin, VEGF121/rGel 18,38–40
Ovarian cancer In vitro TPPS2a (Liposomally encapsulated) Saporin,
(EGF-) Saporin
21,41
Sarcoma In vitro TPCS2a, TPPS2a (anti-CD133-) Saporin, (IM7-) Saporin, Gelonin 34,42,43
In vivo TPCS2a, AlPcS2a Bleomycin, Gelonin 38,44–47
Bladder cancer In vitro Hypericin
1, TPCS2a,
AlPcS2a, TPPS2a
Mitoxantrone, Bleomycin, (scFvMEL-) rGelonin 31,35,48
In vivo TPCS2a No drug was used—Establishment of an optimal
PCI treatment based on an orthotopic
bladder cancer model
49
Glioma In vitro AlPcS2a, TPPS2a Bleomycin, (scFvMEL-)rGelonin 35,50
In vivo AlPcS2a Bleomycin and ETXp (Clostridium
perfringens epsilon protoxin)
51
Skin cancer In vitro TPPS2a, AlPcS2a, 3-THPP
2 (EGF-) Saporin, (Cetuximab-) Saporin, Gelonin,
(MOC31-) Gelonin
16,21,22,29
In vivo AlPcS2a (scFvMEL-)rGelonin 35
Prostate
cancer
In vitro TPPS2a (Cetuximab-)Saporin, (IM7-) Saporin 22,34
Pancreatic
cancer
In vitro TPCS2a (anti-CD133-)Saporin, (IM7-) Saporin 34,52
Lung cancer In vitro AlPcS2a, 3-THPP
2 (MOC31-)Gelonin 29
Several types of cancer have been subjected to PCI both in vitro and in vivo using different photosensitisers, and cytotoxic agents. In some cases
the cytotoxin is actively targeted and the accompanying targeting ligand is shown in parentheses.
1Although these photosensitisers will localise in organelle membranes, they are far less speciﬁc to endolysosomes and are thus less efﬁcient as
photosensitisers for Photochemical Internalisation.
2In certain cases 3-THPP was used as a negative control for PCI.
Abbreviations: TPCS2a—disulfonated tetraphenyl chlorin; TPPS2a—disulfonated tetraphenyl porphine; ZnPc—zinc phthalocyanine; BPD-MA—
benzoporphyrin derivative monoacid; 3-THPP—tetra (3-hydroxyphenyl) porphyrin; AlPcS2a—aluminium phthalocyanine disulfonate; DPc—dendrimer
phthalocyanine; mTHPC—m-tetra(hydroxyphenyl)chlorin.
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progression, and could enable a reduction in the required
dose of ionising radiation.
46 This may be relevant to future
clinical studies where a combination of therapeutic techni-
ques is employed.
As discussed above, amphiphilic photosensitisers are gen-
erally used for PCI but in a recent in vitro study on human
head and neck cancer cell lines, bleomycin PCI has been
shown to be effective when a lipophilic photosensitiser is
administered using liposomal formulations which should
favour uptake by endocytosis. However for this approach to
work effectively in vivo the photosensitiser would have to
remain conﬁned to the liposome once in circulation.
27
PCI has also been used successfully with anthracycline
drugs, doxorubicin (0.5 kDa) and mitoxantrone (0.4 kDa),
which inhibit DNA and RNA synthesis. Although these are
relatively small molecules, they are weak bases which may be
retained within acidic lysosomes due to ion-trapping of the
protonated form. In 2006, Lou et al. compared PCI in doxor-
ubicin sensitive and doxorubicin resistant MCF-7 breast can-
cer cell lines and showed that PCI overcame endosomal
entrapment of the doxorubicin in the resistant cell line by
promoting transport of doxorubicin to cell nuclei.
30 PCI was
also effective in mitoxantrone-resistant cells using hyperi-
cin.
31 Multidrug-resistance in uterine sarcoma cells was
shown to be abrogated using PCI by Selbo et al.,
24 and the
same team later hypothesised that the endolysosomal localisa-
tion of the PS could protect them from efﬂux via the ATP-
binding cassette transporter involved in MDR (ABCG2).
32
Macromolecular toxins—Ribosome inactivating proteins (RIP)
Type 1 ribosome inactivating protein (RIP) inhibitors such as
gelonin and saporin (approximately 30 kDa MWt), which are
plant-derived are candidate chemotherapy agents but require
cytosolic delivery. Gelonin and saporin are both highly toxic
but subject to endolysosomal sequestration and degradation,
and have therefore been widely investigated for PCI stud-
ies.
9,16,20,34,42,44 Berg et al. used the NHIK 3025 cervical carci-
noma cell line exposed to a combination of gelonin and
photosensitisers (TPPS2a or AlPcS2a).
9 Up to a 200-fold
increase in cell death was seen compared to either treatment
alone, thus conﬁrming a synergistic effect. A similar study
was carried out by Selbo et al.,
20 in which gelonin was
released from endosomes after PCI; yet, if PCI was delayed
and gelonin was found in lysosomes rather than early endo-
somes, cell killing efﬁciency was reduced owing to drug deg-
radation within lysosomes.
20 THX melanoma cells were also
exposed to gelonin and AlPcS2a to determine the difference
in gelonin-induced cytotoxicity using a light—“before” or —
“after” approach. A light-before strategy signiﬁcantly
enhanced gelonin’s cytotoxicity
16 in agreement with the
aforementioned ﬁndings.
20 Nevertheless, the use of either
PCI strategy will depend on speciﬁc conditions of the study,
and the compounds being delivered.
16,21,22,28 Dietze et al.
completely eradicated sarcoma induced in mice in 50% of
gelonin PCI treated animals, and showed signiﬁcantly delayed
tumour regrowth in the remaining 50% compared to PDT or
non-treated groups.
44 Saporin is another type 1 RIP inhibitor
which has been studied with enhanced cytotoxicity observed
using PCI.
18,19 Additional studies on saporin in relation to
targeted PCI will be reviewed below.
Macromolecular drug carriers
PCI is well suited for the delivery of macromolecular drug
carriers, such as dendrimers and other nanocarriers, which
owing to their size are taken up by endocytosis, thereby lim-
iting the efﬁcacy of the drug which then has to escape from
the endolysosomes to reach its target site. Fretz et al. investi-
gated cytotoxicity induced using liposomes containing toxins
such as saporin by PCI.
41 Cationic liposomes exhibited the
highest cellular uptake and resulted in the greatest reduction
in cell viability, whereas no cytotoxicity was observed when
saporin was delivered without PCI using liposomes or on its
own.
41 Similarly, a better outcome was seen when loading
doxorubicin in PEG liposomes also containing chlorin e6
incorporated within the membrane, as opposed to liposomes
loaded with doxorubicin or chlorin e6 on their own.
53
Pasparakis et al. recently developed polymeric nanocar-
riers based on ketals which were co-loaded with camptothe-
cin (0.35 kDa) and the photosensitiser haematoporphyrin
which were administered to HeLa cells.
54 The structure was
designed to be degradable in acidic lysosomes thereby releas-
ing the lipid soluble haematoporphyrin to localise in mem-
branes for PCI. A synergistic enhancement in cytotoxicity
was observed using PCI.
54 A similar approach has also been
applied for gene transfection using biodegradable polyamino
acid carriers.
55 A nanocarrier based on chitosan bearing a
covalently bound porphyrin resulted in successful PCI trans-
fection of EGFP in human colon carcinoma cells in vitro.
56
The same method could be applied for cytotoxic drug deliv-
ery. The authors hypothesised that in the presence of lipid
membranes, the carrier structure was able to unfold allowing
the hydrophobic porphyrin to be inserted into the lipid
membrane. PCI could similarly be applied to the delivery of
small molecule carrier systems (SMoC) in the delivery of
siRNA or miRNA.
57
Targeted Strategies
Endothelial growth factor receptor (EGFR)
EGFR targeted PCI has been the focus of several studies,
where the RIP inhibitor saporin has been conjugated to anti-
EGFR molecules.
21,22,32 EGFR up-regulation on the cell sur-
face has also been associated with drug resistance.
58,59 Weyer-
gang et al. in 2006
21 and Selbo et al. in 2012
32 showed
synergistic cytotoxicity using PCI delivery of saporin when
targeted with EGF against EGFR positive breast, ovarian and
skin carcinoma cells.
21,32 Similarly, CetuximabV R-saporin PCI
has also been used, directed against EGFR in colorectal and
prostate cancer cells, where it was shown that targeted-
saporin led to improved cytotoxicity as opposed to almost no
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untargeted streptavidin-saporin.
22
Endothelial glycoprotein-2
Endothelial glycoprotein-2 (EGP-2), is overexpressed in most
carcinomas.
29 Gelonin has been covalently linked to MOC31
(an antibody recognising EGP-2) and has been used in several
cancer models.
29,37,39 A PCI-based synergy was found between
gelonin and two photosensitisers (TPPS2a and AlPcS2a), with a
greater effect seen with the targeted MOC31-gelonin in a small
cell lung carcinoma cell line (NCI-H146). Lower cytotoxicity
was seen with MOC31-gelonin alone, but were equally efﬁcient
on EGP-2 antigen negative cells.
29
The same study was performed using WiDr human colorectal
cells in vitro
37 using 5-aminolaevulinic acid-induced porphyrin
photosensitisation. MOC31-gelonin was combined with AlPcS2a
to treat mice bearing subcutaneous WiDr tumours, where 20 days
after PCI treatment in 6/9 cases tumours were completely elimi-
nated. Moreover, no weight variation was seen in the animals and
skin damage was resolved 3 weeks after therapy.
39
Human epidermal growth factor receptor 2
HER2 is overexpressed in 25% of all breast cancer cases
and it is used to determine progression and prognosis.
60,61
Based on this, Berstad et al. in 2012
28 combined trastuzumab
(HerceptinV R)-saporin and a chlorin photosensitiser to com-
pare PDT versus PCI induced cell killing on either HER2
1 or
HER2
2 breast cancer cells.
28 Light administration post expo-
sure of cells to (HerceptinV R)-saporin in PCI was far superior
in cell killing compared to PDT and the PCI light-before
treatment. The authors hypothesised that photooxidative
damage to HER2 with the light-before treatment resulted in
less efﬁcient drug delivery.
28 Gelonin was similarly targeted
against several breast cancer cell lines showing different levels
of expression of HER-2 receptor,
33 and it was shown that in
addition to toxin uptake, relative cellular sensitivity to the
toxin is also an important factor affecting PCI efﬁcacy.
33
Progenitor marker gp240
The progenitor marker gp240 has been found to be relevant in
lobular breast carcinomas, gliomas and melanomas.
62 Accord-
ingly, Selbo et al.
35 used a fusion toxin consisting of a
recombinant single chain antibody against gp240 and gelonin
(scFvMEL/rGel), which was delivered by PCI using either of
two photosensitisers (AlPcS2a and TPPS2a). This fusion toxin
was used to demonstrate the potential of PCI for skin cancer
treatment in vivo (A-375 cells), as well as malignant glioma
(U87MG) and lobular breast carcinoma (MA11) cells in
vitro.
35 Furthermore, the synergistic PCI effect of scFvMEL/
rGel was largely more effective than PDT-, chemo- or non-
treated groups.
35 In the T24 bladder cell line (gp240 negative)
no difference was observed between targeted and non-targeted
PCI. Equally, as already suggested by Berstad et al.,
28 cell anti-
gens can be damaged by light exposure, resulting in a lower
uptake of antibody-fused toxins; therefore this factor needs to
be considered when choosing an appropriate PCI protocol.
Cd133
PCI has been used to successfully target cells expressing
CD133, a surface molecule which has been described as a
marker for stem-like cancer cells exhibiting resistance to che-
motherapeutic agents and resulting in a poor prognosis.
43,52
Fibrosarcoma and liposarcoma cells in vitro were exposed to
saporin bound to antibodies against two different epitopes of
CD133, combined with TPCS2a and light.
43 Administration
of anti-CD133 caused some cytotoxicity on its own, which
could be related to iron uptake pathways and induction of
dedifferentiation in cells. PCI-treated cells in vitro, were able
to delay in vivo tumour growth in 2/3 cases and no tumour
regrowth occurred in 1/6 cases. PDT studies in vitro seemed
to trigger cellular proliferative signals, which would correlate
with the tumour regrowth observed in vivo.
43
A similar study was conducted on WiDr colorectal cells
(CD133
high, 95% expression), a pancreatic cancer cell line with a
small population of CD133
1 (BxPC-3, <4% expression) and a
prostate cancer cell line which is CD133
low expressing, (Du-145,
0.7% expression).
52 In the colorectal cancer cells, CD133-
saporin PCI was able to almost completely eliminate viability at
a dose as low as 10 fM; yet, results with cells exposed to 0.8 PM
of unconjugated saporin, were similar to PDT.
52 Pancreatic can-
cer cells (BxPC-3), showed a 50% reduction in cell viability,
which seemed to be exclusively caused by the bound anti-
CD133. After PCI, cell viability was further reduced by 90%,
despite showing resistance to PDT. Once again these results cor-
relate with the exposure of DU 145 cells (lacking CD133) to
anti-CD133-saporin, in which case, toxicity induced by either
toxin alone or targeted was similar.
52 Importantly, high prolifer-
ative capacity and tumour formation ability was conﬁrmed with
cells that highly express CD133 in vitro and in vivo; thus, tar-
geted PCI could be in this case be a highly effective treatment
against aggressive, and rapidly metastasising tumours.
Additional cancer stem cell markers such as CD44 or epi-
thelial cell adhesion molecule (EpCAM) have also been the
target of PCI treatment, conﬁrming the efﬁcacy of relevant
immunotoxins based on saporin.
34,63
Potential Advantages of PCI
Overcoming chemotherapy-drug resistance
In previous sections we have reviewed several studies showing
that PCI is effective in treating drug-resistant cell
lines.
23,24,28,30–32,34,36 It has also been proposed that photooxida-
tive damage to efﬂux pumps can counteract chemotherapy
resistance. An example of this was described by Lu et al.w h o
used encapsulation of PS in micellar structures, and in addition
to overcoming doxorubicin resistance in MCF-7 resistant cells
both in vitro and in vivo, they found in the doxorubicin resist-
ant tumours, the greatest antitumour effect was seen by treating
with light-before PCI. It was thought that P-glycoprotein
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nuclear accumulation of doxorubicin.
36
Potential as an adjuvant to surgical resection
Within a tumour non-proliferating cells are usually found in
the centre, whereas proliferating cells generally reside in the
periphery of an actively growing tumour mass. Norum et al.
demonstrated higher efﬁcacy of bleomycin PCI compared to
PDT towards the periphery of a murine ﬁbrosarcoma.
45 In a
subsequent study using PDT or PCI to treat the tumour bed
after surgical resection, Norum et al. demonstrated that PCI
with surgery was able to induce a signiﬁcant delay in tumour
growth compared to surgery, and PDT in combination with
surgery.
47 The lower efﬁcacy of PDT with surgery is consist-
ent with the lower sensitivity of cells at the tumour margin
to PDT compared to PDT. This study suggests that PCI may
have a role as an adjuvant to surgical resection to ensure
complete tumour removal.
47
Antivascular effects of PCI
For cancer therapy PCI has generally been aimed at enhancing
delivery within the tumour cells. However, recent work has shown
that PCI is also capable of affecting vascular structures
40,45,64
which is relevant to treatment of tumours containing drug resist-
ant cells which will die if the tumour microvasculature is dam-
aged. Vascular shutdown has been widely described as an
important component of the PDT effect. In 2009, Norum et al.
also conﬁrmed vascular shutdown post-PCI occurring at a later
stage than for PDT.
45 Accordingly, endothelial cells as potential
PCI targets have been studied. The combined effect of either pho-
tosensitiser TPPS2a or AlPcS2a with saporin was recently com-
pared using human vascular endothelial cells (HUVECs) and
ﬁbrosarcoma cells.
64 Both photosensitisers were more efﬁciently
taken up by HUVEC cells and found to be located in endocytic
vesicles. These results suggest more attention should be given to
vascular endothelial cells during PCI treatment given the capacity
of both PDT and PCI to act on endothelial cells, which in a physi-
ological environment could be translated into vascular shutdown.
Clinical Work With PCI
A single-centre (University College Hospitals—UCH) dose-
escalation phase I clinical trial was successfully completed on
22 patients in 2013 with superﬁcial skin and head and neck
neoplasms combining bleomycin and AmphinexV R (Clinical-
Trials.gov identiﬁer: NCT00993512). No adverse reactions
were found so a multi-centre phase II study (ClinicalTrials.-
gov identiﬁer: NCT01872923) is now being carried out
between several European centres (UK, Netherlands, France,
Germany and Lithuania), which will focus on both superﬁcial
and deeper head and neck tumours using interstitial illumi-
nation. In addition, a phase I/II dose escalation study of PCI
of gemcitabine using AmphinexV R, followed by gemcitabine/
cisplatin chemotherapy has recently commenced for
advanced inoperable cholangiocarcinomas (ClinicalTrials.gov
identiﬁer: NCT01900158).
Conclusions and Future of PCI
Many research groups worldwide are investigating PCI, and
there is growing evidence supporting its potential as a drug
delivery system in cancer treatment. PCI is a very versatile
technique which has been shown to be effective for delivery
of drugs exhibiting diverse physicochemical properties and
sizes and may ﬁnd application for cytosolic delivery in the
emerging ﬁeld of “nanomedicine.” Site-speciﬁc light applica-
tion to the target lesion results in the focal delivery of thera-
peutic compounds, thereby minimising damage to normal
adjacent tissue
8,15 although this means that PCI is only suita-
ble for local treatment of cancer. PCI could potentially widen
the range of chemotherapy options to include relatively cyto-
toxic chemotherapy drugs whose dosages could be lowered
while maintaining their therapeutic effect. Further work is
required on optimising light dosimetry for PCI since it relies
on adequate light doses reaching the tumour extremities, and
on optimisation of the drug and photosensitiser doses and
timing of administration. These complications will have to be
addressed in clinical trials in order for PCI to gain wide-
spread acceptance. Photooxidative damage induced by PDT
has been shown to elicit an immune response, albeit variable
in nature,
65–70 but it will be important to establish whether
PCI is also able to trigger such a response which could help
improve tumour control. In conclusion, PCI is a promising
means of enhancing chemotherapy and like PDT may ﬁnd
application for focal treatment of a wide range of solid
tumours including pancreatic and prostate cancer.
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